A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating Drugs
- 1 December 1974
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 71 (12) , 5078-5082
- https://doi.org/10.1073/pnas.71.12.5078
Abstract
The designing of DNA intercalating drugs with high DNA affinity in the series of ellipticine has led to a new antitumoral agent, 9-hydroxyellipticine, which has a high DNA affinity, a high activity on L 1210 mice leukemia, and a lack of toxicity at therapeutic dose. The possible correlations among chemical structure, DNA reactivity, and pharmacological activity of DNA intercalating drugs are discussed.Keywords
This publication has 18 references indexed in Scilit:
- A fluorescent complex between ethidium bromide and nucleic acids: Physical—Chemical characterizationPublished by Elsevier ,2004
- Etude spectrophotométrique du complexe DNA-daunorubicineBiochimie, 1973
- Double Helix at Atomic ResolutionNature, 1973
- The change of the torsion of the DNA helix caused by intercalation: II — Measurement of the relative change of torsion induced by various intercalating drugsBiochimie, 1971
- A new DNA intercalating drug: Methoxy‐9‐ellipticineFEBS Letters, 1971
- Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: Evidence for molecular models involving intercalationJournal of Molecular Biology, 1970
- DNA OF BACTERIOPHAGE PM2: A CLOSED CIRCULAR DOUBLE-STRANDED MOLECULEProceedings of the National Academy of Sciences, 1969
- Relaxation studies of the proflavine-DNA complex: The kinetics of an intercalation reactionJournal of Molecular Biology, 1969
- Alkaloids of Ochrosia maculata Jacq. (Ochrosia borbonica Gmel.)Journal of Pharmaceutical Sciences, 1968
- Actinomycin binding to DNA: Mechanism and specificityJournal of Molecular Biology, 1965